$TGTX
TG THERAPEUTICS, INC. Stock $tgtx

$tgtx Overview Financials Valuation SEC Filings Company Website

2021 Form 10-K Financial Statement

#000155837022002617 Filed on March 01, 2022

Income Statement

Concept	2021	2020 Q4	2020
Revenue	$6.689M	$40.00K	$152.0K
YoY Change	4300.66%	0.0%	0.0%
Cost Of Revenue	$790.0K
YoY Change
Gross Profit	$5.899M
YoY Change
Gross Profit Margin	88.19%
Selling, General & Admin	$128.1M	$43.86M	$107.9M
YoY Change	18.77%	521.25%	617.71%
% of Gross Profit	2171.38%
Research & Development	$222.6M	$42.96M	$165.9M
YoY Change	34.17%	38.85%	7.6%
% of Gross Profit	3773.16%
Depreciation & Amortization	$282.0K	$50.00K	$158.0K
YoY Change	78.48%	66.67%	58.0%
% of Gross Profit	4.78%
Operating Expenses	$351.5M	$86.82M	$273.7M
YoY Change	28.39%	128.49%	61.78%
Operating Profit	-$344.8M		-$273.6M
YoY Change	26.02%		61.84%
Interest Expense	$5.638M	-$1.290M	$6.329M
YoY Change	-10.92%	-32.11%	19.71%
% of Operating Profit
Other Income/Expense, Net	-$3.331M	-$150.0K	-$5.787M
YoY Change	-42.44%	-151.72%	51.65%
Pretax Income	-$348.1M	-$88.22M	-$279.4M
YoY Change	24.6%	122.95%	161512.42%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$348.1M	-$88.22M	-$279.4M
YoY Change	24.6%	122.94%	61.61%
Net Earnings / Revenue	-5204.08%	-220550.0%	-183803.29%
Basic Earnings Per Share	-$2.63		-$2.42
Diluted Earnings Per Share	-$2.633M	-$710.4K	-$2.422M
COMMON SHARES
Basic Shares Outstanding	132.2M	131.5M	115.3M
Diluted Shares Outstanding	132.2M		115.3M

Balance Sheet

Concept	2021	2020 Q4	2020
SHORT-TERM ASSETS
Cash & Short-Term Investments	$314.8M	$605.4M	$605.4M
YoY Change	-48.01%	331.2%	331.2%
Cash & Equivalents	$298.9M	$553.4M	$153.6M
Short-Term Investments	$15.88M	$52.00M	$52.00M
Other Short-Term Assets	$14.81M	$1.083M	$6.300M
YoY Change	135.13%	77.25%	-27.59%
Inventory
Prepaid Expenses
Receivables	$1.389M
Other Receivables	$0.00
Total Short-Term Assets	$331.0M	$611.7M	$611.7M
YoY Change	-45.89%	310.15%	309.99%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.07M	$481.0K	$11.80M
YoY Change	-6.2%	70.57%	0.0%
Goodwill		$799.0K
YoY Change		0.0%
Intangibles
YoY Change
Long-Term Investments	$35.53M
YoY Change
Other Assets	$1.264M	$1.300M	$1.300M
YoY Change	-2.77%	0.0%	0.0%
Total Long-Term Assets	$48.66M	$13.90M	$13.90M
YoY Change	250.1%	0.28%	0.72%
TOTAL ASSETS
Total Short-Term Assets	$331.0M	$611.7M	$611.7M
Total Long-Term Assets	$48.66M	$13.90M	$13.90M
Total Assets	$379.6M	$625.6M	$625.6M
YoY Change	-39.32%	283.8%	283.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$51.29M	$37.00M	$37.00M
YoY Change	38.63%	23.33%	23.33%
Accrued Expenses	$11.60M	$10.10M	$10.10M
YoY Change	14.88%	87.04%	87.04%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$975.0K	$22.18M	$23.10M
YoY Change	-95.78%		11450.0%
Total Short-Term Liabilities	$65.38M	$87.55M	$87.60M
YoY Change	-25.36%	3.68%	3.79%
LONG-TERM LIABILITIES
Long-Term Debt	$66.79M	$7.716M	$7.700M
YoY Change	767.38%	-73.37%	-73.45%
Other Long-Term Liabilities	$10.30M	$11.00M	$11.00M
YoY Change	-6.33%		0.0%
Total Long-Term Liabilities	$77.09M	$7.716M	$18.70M
YoY Change	312.26%	-73.37%	-53.25%
TOTAL LIABILITIES
Total Short-Term Liabilities	$65.38M	$87.55M	$87.60M
Total Long-Term Liabilities	$77.09M	$7.716M	$18.70M
Total Liabilities	$142.5M	$106.3M	$106.3M
YoY Change	34.03%	-14.56%	-14.55%
SHAREHOLDERS EQUITY
Retained Earnings		-$980.6M
YoY Change		39.84%
Common Stock		$141.0K
YoY Change		29.36%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$200.0K
YoY Change		-14.53%
Treasury Stock Shares		$41.31K
Shareholders Equity	$237.2M	$519.4M	$519.4M
YoY Change
Total Liabilities & Shareholders Equity	$379.6M	$625.6M	$625.6M
YoY Change	-39.32%	283.8%	283.8%

Cashflow Statement

Concept	2021	2020 Q4	2020
OPERATING ACTIVITIES
Net Income	-$348.1M	-$88.22M	-$279.4M
YoY Change	24.6%	122.94%	61.61%
Depreciation, Depletion And Amortization	$282.0K	$50.00K	$158.0K
YoY Change	78.48%	66.67%	58.0%
Cash From Operating Activities	-$295.6M	-$52.03M	-$214.5M
YoY Change	37.82%	71.15%	61.52%
INVESTING ACTIVITIES
Capital Expenditures	$401.0K	-$160.0K	$357.0K
YoY Change	12.32%	433.33%	172.52%
Acquisitions
YoY Change
Other Investing Activities	$69.00K	-$51.92M	-$24.15M
YoY Change	-100.29%	-129900.0%	3993.22%
Cash From Investing Activities	-$332.0K	-$52.08M	-$24.51M
YoY Change	-98.65%		3313.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	41.42M	403.4M	679.8M
YoY Change	-93.91%	310.16%	232.9%
NET CHANGE
Cash From Operating Activities	-295.6M	-52.03M	-214.5M
Cash From Investing Activities	-332.0K	-52.08M	-24.51M
Cash From Financing Activities	41.42M	403.4M	679.8M
Net Change In Cash	-254.5M	299.3M	440.8M
YoY Change	-157.75%	340.44%	523.59%
FREE CASH FLOW
Cash From Operating Activities	-$295.6M	-$52.03M	-$214.5M
Capital Expenditures	$401.0K	-$160.0K	$357.0K
Free Cash Flow	-$296.0M	-$51.87M	-$214.9M
YoY Change	37.78%	70.79%	61.63%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001001316
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	1-32639
CY2021	dei	Entity Registrant Name EntityRegistrantName	TG THERAPEUTICS, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	36-3898269
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	2 Gansevoort St.
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	9th Floor
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10014
CY2021	dei	City Area Code CityAreaCode	212
CY2021	dei	Local Phone Number LocalPhoneNumber	554-4484
CY2021	dei	Security12b Title Security12bTitle	Common Stock
CY2021	dei	Trading Symbol TradingSymbol	TGTX
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	4935702168
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	142817329
CY2021	dei	Auditor Name AuditorName	KPMG LLP
CY2021	dei	Auditor Location AuditorLocation	New York, NY
CY2021	dei	Auditor Firm AuditorFirmId	185
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	298887000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	553439000
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	15876000
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	51987000
CY2021Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	1389000
CY2021Q4	tgtx	Prepaid Research And Development PrepaidResearchAndDevelopment	11929000
CY2020Q4	tgtx	Prepaid Research And Development PrepaidResearchAndDevelopment	5231000
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2884000
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1083000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	330965000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	611740000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1264000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1259000
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	35533000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8629000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9312000
CY2021Q4	tgtx	Leasehold Interest LeaseholdInterest	1839000
CY2020Q4	tgtx	Leasehold Interest LeaseholdInterest	2051000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	600000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	481000
CY2021Q4	us-gaap	Goodwill Goodwill	799000
CY2020Q4	us-gaap	Goodwill Goodwill	799000
CY2021Q4	us-gaap	Assets Assets	379629000
CY2020Q4	us-gaap	Assets Assets	625642000
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	51294000
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	37014000
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1512000
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	18236000
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	975000
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	22179000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1437000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1669000
CY2021Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	10166000
CY2020Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	8456000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	65384000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	87554000
CY2021Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	457000
CY2020Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	610000
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	66788000
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	7716000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9847000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10412000
CY2021Q4	us-gaap	Liabilities Liabilities	142476000
CY2020Q4	us-gaap	Liabilities Liabilities	106292000
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	143292043
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	140617606
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	143250734
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	140576297
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	143000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	141000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1565942000
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1500040000
CY2020Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	41309
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	41309
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	234000
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	234000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1328698000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-980597000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	237153000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	519350000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	379629000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	625642000
CY2021	us-gaap	Revenues Revenues	6689000
CY2020	us-gaap	Revenues Revenues	152000
CY2019	us-gaap	Revenues Revenues	152000
CY2021	tgtx	Cost Of Product Revenue CostOfProductRevenue	790000
CY2020	tgtx	Cost Of Product Revenue CostOfProductRevenue	0
CY2020	tgtx	Non Cash Stock Expense Associated With In Licensing Agreements NonCashStockExpenseAssociatedWithInLicensingAgreements	0
CY2019	tgtx	Non Cash Stock Expense Associated With In Licensing Agreements NonCashStockExpenseAssociatedWithInLicensingAgreements	100000
CY2021	tgtx	Non Cash Compensation Research And Development Expenses NonCashCompensationResearchAndDevelopmentExpenses	24047000
CY2020	tgtx	Non Cash Compensation Research And Development Expenses NonCashCompensationResearchAndDevelopmentExpenses	13962000
CY2019	tgtx	Non Cash Compensation Research And Development Expenses NonCashCompensationResearchAndDevelopmentExpenses	5811000
CY2021	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	198532000
CY2020	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	151934000
CY2019	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	148269000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	222579000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	165896000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	154180000
CY2021	tgtx	Non Cash Compensation Selling General And Administrative Expenses NonCashCompensationSellingGeneralAndAdministrativeExpenses	37227000
CY2020	tgtx	Non Cash Compensation Selling General And Administrative Expenses NonCashCompensationSellingGeneralAndAdministrativeExpenses	66327000
CY2019	tgtx	Non Cash Compensation Selling General And Administrative Expenses NonCashCompensationSellingGeneralAndAdministrativeExpenses	5523000
CY2021	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	90863000
CY2020	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	41523000
CY2019	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	9504000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	128090000
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	107850000
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	15027000
CY2021	us-gaap	Operating Expenses OperatingExpenses	351459000
CY2020	us-gaap	Operating Expenses OperatingExpenses	273746000
CY2019	us-gaap	Operating Expenses OperatingExpenses	169207000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-344770000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-273594000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-169055000
CY2021	us-gaap	Interest Expense InterestExpense	5638000
CY2020	us-gaap	Interest Expense InterestExpense	6329000
CY2019	us-gaap	Interest Expense InterestExpense	5287000
CY2021	us-gaap	Other Income OtherIncome	2307000
CY2020	us-gaap	Other Income OtherIncome	542000
CY2019	us-gaap	Other Income OtherIncome	1471000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3331000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5787000
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3816000
CY2021	us-gaap	Profit Loss ProfitLoss	-348101000
CY2020	us-gaap	Profit Loss ProfitLoss	-279381000
CY2019	us-gaap	Profit Loss ProfitLoss	-172871000
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.63
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.42
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.96
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	132222753
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	115333693
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	88368844
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	24036000
CY2019	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	993000
CY2019	tgtx	Offering Costs OfferingCosts	200000
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	77475000
CY2019Q4	tgtx	Offering Costs At Market OfferingCostsAtMarket	2000000.0
CY2019	tgtx	Issuance Of Common Stock In At Market Offering Net Of Offering Costs IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts	97547000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	11335000
CY2019	tgtx	Stock Issued During Period Value In Licensing Agreements StockIssuedDuringPeriodValueInLicensingAgreements	100000
CY2019	us-gaap	Profit Loss ProfitLoss	-172871000
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	38615000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	146000
CY2020	tgtx	Offering Costs OfferingCosts	29900000
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	462229000
CY2020Q4	tgtx	Offering Costs At Market OfferingCostsAtMarket	4000000.0
CY2020	tgtx	Issuance Of Common Stock In At Market Offering Net Of Offering Costs IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts	217452000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	80289000
CY2020	us-gaap	Profit Loss ProfitLoss	-279381000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	519350000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	216000
CY2021	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	2195000
CY2021	tgtx	Offering Costs OfferingCosts	-204000
CY2021Q4	tgtx	Offering Costs At Market OfferingCostsAtMarket	100000
CY2021	tgtx	Issuance Of Common Stock In At Market Offering Net Of Offering Costs IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts	2423000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	61274000
CY2021	us-gaap	Profit Loss ProfitLoss	-348101000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	237153000
CY2021	us-gaap	Profit Loss ProfitLoss	-348101000
CY2020	us-gaap	Profit Loss ProfitLoss	-279381000
CY2019	us-gaap	Profit Loss ProfitLoss	-172871000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	61274000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	80289000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	11335000
CY2021	tgtx	Shares Issued In Connection With In Licensing Agreement SharesIssuedInConnectionWithInLicensingAgreement	0
CY2020	tgtx	Shares Issued In Connection With In Licensing Agreement SharesIssuedInConnectionWithInLicensingAgreement	0
CY2019	tgtx	Shares Issued In Connection With In Licensing Agreement SharesIssuedInConnectionWithInLicensingAgreement	100000
CY2021	us-gaap	Depreciation Depreciation	282000
CY2020	us-gaap	Depreciation Depreciation	158000
CY2019	us-gaap	Depreciation Depreciation	100000
CY2021	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	517000
CY2020	us-gaap	Investment Income Amortization Of Discount InvestmentIncomeAmortizationOfDiscount	30000
CY2019	us-gaap	Investment Income Amortization Of Discount InvestmentIncomeAmortizationOfDiscount	257000
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1080000
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	925000
CY2019	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	772000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	212000
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	216000
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	182000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1896000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2325000
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2519000
CY2021	tgtx	Change In Fair Value Of Notes Payable ChangeInFairValueOfNotesPayable	578000
CY2020	tgtx	Change In Fair Value Of Notes Payable ChangeInFairValueOfNotesPayable	-748000
CY2019	tgtx	Change In Fair Value Of Notes Payable ChangeInFairValueOfNotesPayable	-124000
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	8508000
CY2020	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-2257000
CY2019	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-1384000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1389000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0
CY2021	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	15991000
CY2020	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	11631000
CY2019	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-4795000
CY2021	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-2012000
CY2020	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-1988000
CY2019	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-1548000
CY2021	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-16146000
CY2020	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-31505000
CY2019	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	30301000
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-152000
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-152000
CY2019	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-152000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-295634000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-214507000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-132806000
CY2021	tgtx	Proceeds From Maturities ProceedsFromMaturities	55600000
CY2020	tgtx	Proceeds From Maturities ProceedsFromMaturities	43250000
CY2019	tgtx	Proceeds From Maturities ProceedsFromMaturities	29250000
CY2021	tgtx	Payments To Acquire Held To Maturity Securities Short Term PaymentsToAcquireHeldToMaturitySecuritiesShortTerm	55531000
CY2020	tgtx	Payments To Acquire Held To Maturity Securities Short Term PaymentsToAcquireHeldToMaturitySecuritiesShortTerm	67403000
CY2019	tgtx	Payments To Acquire Held To Maturity Securities Short Term PaymentsToAcquireHeldToMaturitySecuritiesShortTerm	29837000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	401000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	357000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	131000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-332000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-24510000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-718000
CY2021	us-gaap	Proceeds From Repayments Of Secured Debt ProceedsFromRepaymentsOfSecuredDebt	-30000000
CY2020	us-gaap	Proceeds From Repayments Of Secured Debt ProceedsFromRepaymentsOfSecuredDebt	0
CY2019	us-gaap	Proceeds From Repayments Of Secured Debt ProceedsFromRepaymentsOfSecuredDebt	0
CY2021	tgtx	Net Proceeds From Shares New Issues Overallotments NetProceedsFromSharesNewIssuesOverallotments	2219000
CY2020	tgtx	Net Proceeds From Shares New Issues Overallotments NetProceedsFromSharesNewIssuesOverallotments	679680000
CY2019	tgtx	Net Proceeds From Shares New Issues Overallotments NetProceedsFromSharesNewIssuesOverallotments	175021000
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	216000
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	147000
CY2019	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0
CY2021	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	70000000
CY2020	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	0
CY2019	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	29987000
CY2021	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	1016000
CY2020	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0
CY2019	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	795000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	41419000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	679827000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	204213000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-254547000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	440810000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	70689000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	554698000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	113888000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	43199000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	300151000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	554698000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	113888000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	298887000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	553439000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	112637000
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	1264000
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	1259000
CY2019Q4	us-gaap	Restricted Cash RestrictedCash	1251000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	3466000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	4501000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	2622000
CY2021	tgtx	Accrued Financing Costs AccruedFinancingCosts	4165000
CY2020	tgtx	Accrued Financing Costs AccruedFinancingCosts	0
CY2019	tgtx	Accrued Financing Costs AccruedFinancingCosts	988000
CY2021	tgtx	Warrants Issued With Debt Financing WarrantsIssuedWithDebtFinancing	2196000
CY2020	tgtx	Warrants Issued With Debt Financing WarrantsIssuedWithDebtFinancing	0
CY2019	tgtx	Warrants Issued With Debt Financing WarrantsIssuedWithDebtFinancing	993000
CY2021	tgtx	Shares Issued In Connection With In Licensing Agreements Value SharesIssuedInConnectionWithInLicensingAgreementsValue	0
CY2020	tgtx	Shares Issued In Connection With In Licensing Agreements Value SharesIssuedInConnectionWithInLicensingAgreementsValue	0
CY2019	tgtx	Shares Issued In Connection With In Licensing Agreements Value SharesIssuedInConnectionWithInLicensingAgreementsValue	100000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1300000000
CY2021Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	350300000
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">USE OF ESTIMATES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the applicable reporting period. On an ongoing basis, we evaluate our estimates and judgments, including those related to revenue, accrued clinical trial expenses and stock-based compensation. Actual results could differ from those estimates. Such differences could be material to the financial statements.</p>
CY2020Q4	us-gaap	Restricted Cash And Investments RestrictedCashAndInvestments	1300000
CY2021Q4	us-gaap	Restricted Cash And Investments RestrictedCashAndInvestments	1300000
CY2021Q4	us-gaap	Restricted Cash And Investments RestrictedCashAndInvestments	1300000
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">CREDIT RISK</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company maintains its cash and cash equivalents and short-term investments with high-credit quality financial institutions. At times, such amounts may exceed federally-insured limits.</p>
CY2021Q4	tgtx	Prepaid Research And Development PrepaidResearchAndDevelopment	11900000
CY2020Q4	tgtx	Prepaid Research And Development PrepaidResearchAndDevelopment	5200000
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13280608
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11976276
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8361739
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13280608
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11976276
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8361739
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2021	tgtx	Revenue Gross RevenueGross	8172000
CY2021	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	840000
CY2021	tgtx	Trade Discounts And Allowances TradeDiscountsAndAllowances	383000
CY2021	tgtx	Government Rebates And Co Payment Assistance GovernmentRebatesAndCoPaymentAssistance	372000
CY2021	tgtx	Sales Returns And Allowances SalesReturnsAndAllowances	40000
CY2021	tgtx	Gross To Net Adjustments GrossToNetAdjustments	1635000
CY2021	tgtx	Net Product Revenue NetProductRevenue	6537000
CY2021Q4	tgtx	Gross Net Accruals GrossNetAccruals	400000
CY2021Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	51409000
CY2021Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	164000
CY2021Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	51245000
CY2020Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	51987000
CY2020Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	1000
CY2020Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	4000
CY2020Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	51984000
CY2021Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	360000
CY2021Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	360000
CY2020Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	938000
CY2020Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	938000
CY2019Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	190000
CY2020	tgtx	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Interest Accrued Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings	976000
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-228000
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	938000
CY2021	tgtx	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Interest Accrued Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings	1023000
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-1601000
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	360000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	4100000
CY2019Q1	us-gaap	Share Price SharePrice	5.87
CY2019Q1	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	27500000
CY2019Q1	tgtx	Payments Of Underwriting Discounts And Offering Expenses PaymentsOfUnderwritingDiscountsAndOfferingExpenses	200000
CY2020Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	41309
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	41309
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	200000
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	200000
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1916900
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	815000
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.50
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	126170
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	6.10
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2605730
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.73
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y11M1D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	11706110
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	75000
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.21
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	35814
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.10
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	118750
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	10.16
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2526166
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.99
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y1M6D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	115472832
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	52694
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.10
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	5935
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.10
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2467537
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.06
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y11M26D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	29503551
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1368106
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.57
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y18D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	17023532
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1088750
CY2021Q4	us-gaap	Other Long Term Debt OtherLongTermDebt	70000000
CY2020Q4	us-gaap	Other Long Term Debt OtherLongTermDebt	30000000
CY2021Q4	tgtx	End Of Term Fee EndOfTermFee	5140000
CY2020Q4	tgtx	End Of Term Fee EndOfTermFee	975000
CY2021Q4	tgtx	Long Term Debt Gross LongTermDebtGross	75140000
CY2020Q4	tgtx	Long Term Debt Gross LongTermDebtGross	30975000
CY2021Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	7377000
CY2020Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	1080000
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	67763000
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	29895000
CY2021Q4	tgtx	Long Term Debt Excluding Principal Payments LongTermDebtExcludingPrincipalPayments	67763000
CY2020Q4	tgtx	Long Term Debt Excluding Principal Payments LongTermDebtExcludingPrincipalPayments	29895000
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	975000
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	22179000
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	66788000
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	7716000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	2656000
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	2651000
CY2021	us-gaap	Lease Cost LeaseCost	2154000
CY2020	us-gaap	Lease Cost LeaseCost	2656000
CY2019	us-gaap	Lease Cost LeaseCost	2651000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	2154000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1437000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1669000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9847000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10412000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	11284000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	12081000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2035000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2040000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1924000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1653000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1678000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	8219000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	17549000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	6265000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	11284000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	367400000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	276700000
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1300000000
CY2021Q4	tgtx	Research And Development Carryforward ResearchAndDevelopmentCarryforward	35700000
CY2021Q4	tgtx	Business Interest Expense Carryforward BusinessInterestExpenseCarryforward	9800000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	295985000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	223685000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	35665000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	27558000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	32356000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	22381000
CY2021Q4	tgtx	Deferred Tax Asset Disallowed Interest DeferredTaxAssetDisallowedInterest	2434000
CY2020Q4	tgtx	Deferred Tax Asset Disallowed Interest DeferredTaxAssetDisallowedInterest	1855000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1006000
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1224000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	367446000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	276703000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	367446000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	276703000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-348101000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-279381000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-172871
CY2021	us-gaap	Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems	-73101000
CY2020	us-gaap	Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems	-58670000
CY2019	us-gaap	Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems	-36303
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-3445000
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-10801000
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2128
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	8337000
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	5265000
CY2019	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	7266
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	867000
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1065000
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	641
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-6726000
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-1558000
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1292
CY2021	tgtx	Effects Of Federal Tax Reform Rate Changes EffectsOfFederalTaxReformRateChanges	0
CY2020	tgtx	Effects Of Federal Tax Reform Rate Changes EffectsOfFederalTaxReformRateChanges	-14763000
CY2019	tgtx	Effects Of Federal Tax Reform Rate Changes EffectsOfFederalTaxReformRateChanges	0
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	90742000
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	89992000
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	43764
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2021Q4	us-gaap	Contractual Obligation ContractualObligation	93594000
CY2021Q4	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	3038000
CY2021Q4	us-gaap	Contractual Obligation Due In Second And Third Year ContractualObligationDueInSecondAndThirdYear	4290000
CY2021Q4	us-gaap	Contractual Obligation Due In Fourth And Fifth Year ContractualObligationDueInFourthAndFifthYear	77996000
CY2021Q4	us-gaap	Contractual Obligation Due After Fifth Year ContractualObligationDueAfterFifthYear	8270000
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	2200000
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	2700000
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	2700000

Files In Submission

Name	View Source	Status
0001558370-22-002617-index-headers.html	Edgar Link	pending
0001558370-22-002617-index.html	Edgar Link	pending
0001558370-22-002617.txt	Edgar Link	pending
0001558370-22-002617-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tgtx-20211231.xsd	Edgar Link	pending
tgtx-20211231x10k.htm	Edgar Link	pending
tgtx-20211231x10k001.jpg	Edgar Link	pending
tgtx-20211231x10k_htm.xml	Edgar Link	completed
tgtx-20211231xex10d28.htm	Edgar Link	pending
tgtx-20211231xex10d29.htm	Edgar Link	pending
tgtx-20211231xex10d30.htm	Edgar Link	pending
tgtx-20211231xex10d31.htm	Edgar Link	pending
tgtx-20211231xex21d1.htm	Edgar Link	pending
tgtx-20211231xex23d1.htm	Edgar Link	pending
tgtx-20211231xex23d2.htm	Edgar Link	pending
tgtx-20211231xex31d1.htm	Edgar Link	pending
tgtx-20211231xex31d2.htm	Edgar Link	pending
tgtx-20211231xex32d1.htm	Edgar Link	pending
tgtx-20211231xex32d2.htm	Edgar Link	pending
tgtx-20211231_cal.xml	Edgar Link	unprocessable
tgtx-20211231_def.xml	Edgar Link	unprocessable
tgtx-20211231_lab.xml	Edgar Link	unprocessable
tgtx-20211231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TGTX
TG THERAPEUTICS, INC. Stock $tgtx

2021 Form 10-K Financial Statement

#000155837022002617 Filed on March 01, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TGTX TG THERAPEUTICS, INC. Stock $tgtx

2021 Form 10-K Financial Statement

#000155837022002617 Filed on March 01, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TGTX
TG THERAPEUTICS, INC. Stock $tgtx